EZH2 and pancreatic ductal adenocarcinoma: While BAP1 loss was very rare in breast carcinoma [28], pancreatic ductal adenocarcinoma [29], non-small cell lung cancer [30] and colorectal adenocarcinoma [31], EZH2 positivity, on the other hand, was detected in advanced metastatic non-small cell lung cancer [32], 50% of primary pancreatic adenocarcinoma [33], more than 73.7% of primary colorectal carcinoma [34] and 49.8% of primary breast cancer [35].